Envoy Medical (COCH) Financials

Envoy Medical logo
$6.70 -0.03 (-0.45%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$6.64 -0.06 (-0.96%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Envoy Medical

Annual Income Statements for Envoy Medical

This table shows Envoy Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-0.25 -16 -31 -28 -29
Consolidated Net Income / (Loss)
-0.25 -16 -30 -21 -24
Net Income / (Loss) Continuing Operations
-0.25 -16 -30 -21 -24
Total Pre-Tax Income
-0.25 -16 -30 -21 -24
Total Operating Income
-5.20 -8.71 -18 -19 -22
Total Gross Profit
0.00 -0.26 -0.47 -0.52 -0.63
Total Revenue
0.00 0.24 0.32 0.23 0.24
Operating Revenue
- 0.24 0.32 0.23 0.24
Total Cost of Revenue
0.00 0.50 0.79 0.74 0.87
Operating Cost of Revenue
- 0.50 0.79 0.74 0.87
Total Operating Expenses
5.20 8.45 18 19 22
Selling, General & Admin Expense
5.20 2.59 7.26 6.83 7.93
Marketing Expense
- 0.89 1.67 1.73 1.22
Research & Development Expense
- 4.98 8.96 10 12
Total Other Income / (Expense), net
4.95 -7.22 -12 -1.54 -1.49
Interest Expense
0.00 - 0.00 0.82 1.59
Other Income / (Expense), net
4.92 -7.22 -12 -0.72 0.10
Preferred Stock Dividends Declared
- - 1.35 6.68 4.91
Basic Earnings per Share
($0.02) ($1.57) ($2.54) ($1.49) ($1.23)
Weighted Average Basic Shares Outstanding
45.81M 10.12M 12.30M 18.79M 23.26M
Diluted Earnings per Share
($0.02) ($1.57) ($2.54) ($1.49) ($1.23)
Weighted Average Diluted Shares Outstanding
45.81M 10.12M 12.30M 18.79M 23.26M
Weighted Average Basic & Diluted Shares Outstanding
53.13M - 19.60M 21.33M 76.88M

Quarterly Income Statements for Envoy Medical

This table shows Envoy Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-7.64 -5.31 -7.34 -7.69 -6.24 -6.94 -7.75 -7.74 -5.70 -7.27 -5.24
Consolidated Net Income / (Loss)
-6.27 -3.95 -5.96 -4.62 -5.00 -5.69 -6.48 -6.59 -4.35 -5.98 -3.93
Net Income / (Loss) Continuing Operations
-6.27 -3.95 -5.96 -4.62 -5.00 -5.69 -6.48 -6.59 -4.35 -5.98 -3.93
Total Pre-Tax Income
-6.27 -3.95 -5.96 -4.62 -5.00 -5.69 -6.48 -6.59 -4.35 -5.98 -3.93
Total Operating Income
-4.88 -4.85 -4.97 -4.55 -5.11 -5.07 -5.27 -6.39 -5.96 -5.57 -5.54
Total Gross Profit
-0.09 -0.18 -0.13 -0.12 -0.18 -0.16 -0.16 -0.14 -0.27 -0.23 -0.18
Total Revenue
0.06 0.07 0.06 0.04 0.05 0.08 0.04 0.08 0.04 0.05 0.07
Operating Revenue
0.06 0.07 0.06 0.04 0.05 0.08 0.04 0.08 0.04 0.05 0.07
Total Cost of Revenue
0.15 0.25 0.19 0.16 0.23 0.23 0.20 0.21 0.31 0.28 0.24
Operating Cost of Revenue
0.15 0.25 0.19 0.16 0.23 0.23 0.20 0.21 0.31 0.28 0.24
Total Operating Expenses
4.79 4.68 4.84 4.43 4.93 4.91 5.10 6.25 5.69 5.34 5.36
Selling, General & Admin Expense
2.11 1.59 1.69 1.44 1.82 2.07 2.00 1.60 1.88 2.03 2.13
Marketing Expense
0.33 0.50 0.39 0.52 0.36 0.36 0.41 0.10 0.16 0.18 0.16
Research & Development Expense
2.36 2.59 2.76 2.47 2.75 2.49 2.70 4.55 3.64 3.13 3.08
Total Other Income / (Expense), net
-1.39 0.91 -0.99 -0.07 0.11 -0.62 -1.22 -0.20 1.61 -0.41 1.61
Interest Expense
0.04 0.13 0.26 0.38 0.50 0.62 0.47 - 0.00 0.00 0.00
Other Income / (Expense), net
-1.35 1.04 -0.72 0.31 0.60 0.00 -0.75 -0.20 1.61 -0.41 1.61
Preferred Stock Dividends Declared
1.37 1.37 1.38 2.57 1.24 1.25 1.27 1.15 1.35 1.29 1.31
Basic Earnings per Share
($0.41) ($0.29) ($0.39) ($0.40) ($0.29) ($0.32) ($3.55) ($0.27) ($0.08) ($0.07) ($0.50)
Weighted Average Basic Shares Outstanding
18.60M 18.60M 18.62M 18.79M 21.33M 21.38M 2.19M 23.26M 68.93M 104.04M 10.43M
Diluted Earnings per Share
($0.41) ($0.29) ($0.39) ($0.40) ($0.29) ($0.32) ($3.55) ($0.27) ($0.08) ($0.07) ($0.50)
Weighted Average Diluted Shares Outstanding
18.60M 18.60M 18.62M 18.79M 21.33M 21.38M 2.19M 23.26M 68.93M 104.04M 10.43M
Weighted Average Basic & Diluted Shares Outstanding
19.60M 19.60M 20.24M 21.33M 21.33M 21.52M 28.79M 76.88M 76.88M 77.19M 7.74M

Annual Cash Flow Statements for Envoy Medical

This table details how cash moves in and out of Envoy Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.12 -0.94 4.04 1.26 -1.74
Net Cash From Operating Activities
-3.24 -8.81 -17 -18 -18
Net Cash From Continuing Operating Activities
-3.24 -8.81 -17 -18 -18
Net Income / (Loss) Continuing Operations
-0.25 -16 -30 -21 -24
Consolidated Net Income / (Loss)
-0.25 -16 -30 -21 -24
Depreciation Expense
- 0.08 0.13 0.17 0.30
Amortization Expense
0.50 - 0.60 1.86 2.55
Non-Cash Adjustments To Reconcile Net Income
-4.95 7.20 14 1.01 0.27
Changes in Operating Assets and Liabilities, net
1.46 -0.15 -2.05 -0.20 2.43
Net Cash From Investing Activities
-425 -0.22 -0.15 -0.98 -0.18
Net Cash From Continuing Investing Activities
-425 -0.22 -0.15 -0.98 -0.18
Purchase of Property, Plant & Equipment
- -0.22 -0.15 -0.98 -0.18
Net Cash From Financing Activities
428 8.09 21 20 17
Net Cash From Continuing Financing Activities
428 8.09 21 20 17
Repayment of Debt
- - -0.56 -0.92 -0.93
Repurchase of Common Equity
-9.13 - - 0.00 -0.06
Payment of Dividends
- - 0.00 -2.45 -1.82
Issuance of Debt
0.00 8.00 10 20 10
Issuance of Common Equity
- 0.09 0.11 1.75 6.33
Other Financing Activities, net
438 0.00 12 1.82 3.11
Cash Interest Paid
- 0.00 0.03 0.04 0.04

Quarterly Cash Flow Statements for Envoy Medical

This table details how cash moves in and out of Envoy Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
0.73 -3.20 2.68 1.06 -0.18 -0.02 -1.73 0.18 22 -5.57 -5.11
Net Cash From Operating Activities
-5.59 -4.65 -2.62 -5.09 -3.73 -4.46 -4.33 -5.69 -6.06 -5.46 -5.03
Net Cash From Continuing Operating Activities
-5.59 -4.65 -2.71 -5.00 -3.73 -4.47 -4.32 -5.69 -6.06 -5.46 -5.03
Net Income / (Loss) Continuing Operations
-6.27 -3.95 -5.96 -4.62 -5.00 -5.69 -6.48 -6.59 -4.35 -5.98 -3.93
Consolidated Net Income / (Loss)
-6.27 -3.95 -5.96 -4.62 -5.00 -5.69 -6.48 -6.59 -4.35 -5.98 -3.93
Depreciation Expense
0.03 0.04 0.05 0.05 0.06 0.09 0.08 0.08 0.07 0.07 0.08
Amortization Expense
0.27 0.44 0.53 0.62 0.74 0.87 0.71 0.23 0.23 0.24 0.23
Non-Cash Adjustments To Reconcile Net Income
0.40 -0.61 1.64 -0.43 -0.48 -0.05 0.44 0.13 0.36 -0.72 -1.06
Changes in Operating Assets and Liabilities, net
-0.03 -0.57 1.02 -0.62 0.94 0.32 0.93 0.46 -2.37 0.94 -0.34
Net Cash From Investing Activities
-0.11 -0.79 -0.62 0.53 -0.01 -0.00 - -0.17 0.00 -0.01 -0.03
Net Cash From Continuing Investing Activities
-0.11 -0.79 -0.62 0.53 -0.01 -0.00 - -0.17 0.00 -0.01 -0.03
Purchase of Property, Plant & Equipment
-0.11 -0.79 -0.62 0.53 -0.01 -0.00 - -0.17 0.00 -0.01 -0.03
Net Cash From Financing Activities
6.43 2.24 5.92 5.62 3.55 4.44 2.60 6.04 28 -0.11 -0.05
Net Cash From Continuing Financing Activities
6.43 2.24 5.92 5.62 3.55 4.44 2.60 6.04 28 -0.11 -0.05
Repayment of Debt
-0.26 -0.26 -0.18 -0.21 -0.23 -0.24 -0.27 -0.19 -0.21 -0.21 -0.15
Issuance of Common Equity
1.68 - - 0.06 0.00 0.28 2.71 3.34 28 0.10 0.10
Effect of Exchange Rate Changes
- - - - - - - - - - -0.00
Cash Interest Paid
0.01 0.01 0.00 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.00

Annual Balance Sheets for Envoy Medical

This table presents Envoy Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.12 427 2.56 8.27 12 8.56
Total Current Assets
0.03 0.86 1.65 7.46 8.90 6.28
Cash & Equivalents
0.03 0.15 0.18 4.22 5.48 3.74
Accounts Receivable
- - 0.04 0.25 0.82 0.05
Inventories, net
- - 1.30 1.40 1.71 1.55
Prepaid Expenses
0.00 0.71 0.13 1.59 1.38 1.30
Plant, Property, & Equipment, net
0.00 0.00 0.33 0.35 1.28 1.04
Total Noncurrent Assets
0.09 426 1.15 0.46 0.88 0.89
Other Noncurrent Operating Assets
0.09 426 1.15 0.46 0.88 0.89
Total Liabilities & Shareholders' Equity
0.12 427 2.56 8.27 12 8.56
Total Liabilities
0.10 39 39 10 30 20
Total Current Liabilities
0.10 2.68 2.52 7.29 7.54 12
Accounts Payable
0.10 0.62 1.00 1.55 1.65 2.92
Accrued Expenses
0.00 2.06 0.61 4.92 4.00 7.93
Other Current Liabilities
- 0.00 0.59 0.80 0.72 0.69
Total Noncurrent Liabilities
0.00 36 37 2.77 23 8.79
Other Noncurrent Operating Liabilities
0.00 36 3.40 2.36 4.60 8.79
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 425 - - 0.00 0.39
Total Equity & Noncontrolling Interests
0.02 -37 -36 -1.78 -19 -12
Total Preferred & Common Equity
0.02 -37 -36 -1.78 -19 -12
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
0.02 -37 -36 -1.78 -19 -12
Common Stock
0.03 0.00 190 256 266 301
Retained Earnings
-0.00 -37 -226 -257 -285 -313
Accumulated Other Comprehensive Income / (Loss)
- - -0.12 -0.12 -0.12 -0.12

Quarterly Balance Sheets for Envoy Medical

This table presents Envoy Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
21 8.48 6.74 9.40 10 9.90 8.18 30 24 19
Total Current Assets
20 7.73 5.00 7.14 8.31 7.51 5.76 28 22 17
Cash & Equivalents
7.44 4.95 1.75 4.42 5.31 5.29 3.56 25 20 15
Accounts Receivable
1.11 0.22 0.20 0.23 0.07 0.06 0.05 0.05 0.07 0.07
Inventories, net
1.40 1.46 1.58 1.64 1.66 1.59 1.64 1.49 1.58 1.51
Prepaid Expenses
1.00 1.11 1.47 0.84 1.28 1.00 0.51 1.22 0.89 1.37
Plant, Property, & Equipment, net
0.38 0.32 0.63 1.20 1.22 1.14 1.12 0.96 0.92 0.85
Total Noncurrent Assets
0.00 0.87 1.11 1.06 0.85 0.00 1.31 0.85 0.82 0.78
Other Noncurrent Operating Assets
- 0.87 1.11 1.06 0.85 - 1.31 0.85 0.82 0.78
Total Liabilities & Shareholders' Equity
21 8.48 6.74 9.40 10 9.90 8.18 30 24 19
Total Liabilities
16 16 19 28 35 40 16 19 20 20
Total Current Liabilities
13 7.00 8.06 9.07 7.60 8.00 8.99 12 13 14
Accounts Payable
3.38 0.91 1.59 1.76 1.66 1.62 2.68 1.70 2.04 1.58
Accrued Expenses
4.05 5.62 6.29 7.09 5.32 4.96 6.11 9.92 10 12
Other Current Liabilities
0.85 1.51 0.18 0.23 0.56 0.38 3.55 0.56 0.31 0.84
Total Noncurrent Liabilities
4.15 8.39 11 19 27 32 3.36 7.10 7.62 6.03
Other Noncurrent Operating Liabilities
4.15 7.32 2.65 4.50 3.96 3.14 3.36 7.10 7.62 6.03
Commitments & Contingencies
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - 0.13 0.39 0.39 0.39
Total Equity & Noncontrolling Interests
4.79 -7.41 -12 -19 -24 -30 -7.66 10 3.30 -1.53
Total Preferred & Common Equity
4.79 -7.41 -12 -19 -24 -30 -7.66 10 3.30 -1.53
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
4.79 -7.41 -12 -19 -24 -30 -7.66 10 3.30 -1.53
Common Stock
256 258 258 259 267 268 298 329 330 330
Retained Earnings
-251 -265 -270 -278 -291 -298 -306 -319 -326 -332
Accumulated Other Comprehensive Income / (Loss)
-0.12 -0.12 -0.12 -0.12 -0.12 -0.12 -0.12 -0.12 -0.12 -0.12

Annual Metrics And Ratios for Envoy Medical

This table displays calculated financial ratios and metrics derived from Envoy Medical's official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
53,125,000.00 53,125,000.00 39,099,964.00 39,099,964.00 39,099,964.00
DEI Adjusted Shares Outstanding
53,125,000.00 53,125,000.00 39,099,964.00 39,099,964.00 39,099,964.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.30 -0.80 -0.72 -0.73
Growth Metrics
- - - - -
Revenue Growth
0.00% 0.00% 33.33% -28.80% 7.11%
EBITDA Growth
0.00% -7,632.28% -84.17% 38.52% -7.62%
EBIT Growth
0.00% -5,404.01% -87.92% 33.23% -10.95%
NOPAT Growth
0.00% -67.26% -110.88% -4.89% -15.65%
Net Income Growth
0.00% -6,227.87% -87.92% 30.50% -14.24%
EPS Growth
0.00% -7,750.00% -61.78% 41.34% 17.45%
Operating Cash Flow Growth
0.00% -171.69% -94.11% -5.02% -1.40%
Free Cash Flow Firm Growth
0.00% 0.00% -102.58% -42.96% 64.77%
Invested Capital Growth
0.00% -100.68% -111.26% 12.24% -216.06%
Revenue Q/Q Growth
0.00% 315.79% -21.20% -19.06% 15.87%
EBITDA Q/Q Growth
0.00% -276.30% 46.41% 4.13% -16.34%
EBIT Q/Q Growth
0.00% -277.13% 45.17% 3.63% -11.87%
NOPAT Q/Q Growth
0.00% -39.53% -13.64% 10.15% -8.99%
Net Income Q/Q Growth
0.00% -267.72% 45.67% 1.74% -9.03%
EPS Q/Q Growth
0.00% -575.76% 0.00% 0.00% 9.56%
Operating Cash Flow Q/Q Growth
0.00% -20.43% -105.30% 25.22% -3.37%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -102.44% 2.04% 57.77%
Invested Capital Q/Q Growth
0.00% -100.65% 30.59% 42.93% -39.86%
Profitability Metrics
- - - - -
Gross Margin
0.00% -110.13% -149.68% -229.78% -262.66%
EBITDA Margin
0.00% -6,686.92% -9,236.39% -7,974.67% -8,012.45%
Operating Margin
0.00% -3,673.42% -5,809.81% -8,558.22% -9,240.66%
EBIT Margin
0.00% -6,718.57% -9,468.99% -8,879.56% -9,197.51%
Profit (Net Income) Margin
0.00% -6,718.57% -9,468.99% -9,242.22% -9,857.26%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
86.98% 100.00% 100.00% 104.08% 107.17%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -3.16% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -62.02% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% -5.88% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-0.13% -9.04% 157.60% 201.72% 155.22%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -7.42% -552.73% -201.72% -220.60%
Return on Assets (ROA)
0.00% -7.42% -552.73% -209.96% -236.43%
Return on Common Equity (ROCE)
0.01% 1.87% 157.60% 201.72% 157.21%
Return on Equity Simple (ROE_SIMPLE)
0.69% 43.99% 1,684.80% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.64 -6.09 -13 -13 -16
NOPAT Margin
0.00% -2,571.39% -4,066.87% -5,990.76% -6,468.46%
Net Nonoperating Expense Percent (NNEP)
2,263.57% 58.86% 114.82% 144.55% 160.18%
Return On Investment Capital (ROIC_SIMPLE)
- - 936.68% 10,697.78% 128.22%
Cost of Revenue to Revenue
0.00% 210.13% 249.68% 329.78% 362.66%
SG&A Expenses to Revenue
0.00% 1,090.72% 2,298.73% 3,033.78% 3,290.87%
R&D to Revenue
0.00% 2,099.16% 2,834.18% 4,524.00% 5,180.91%
Operating Expenses to Revenue
0.00% 3,563.29% 5,660.13% 8,328.44% 8,978.01%
Earnings before Interest and Taxes (EBIT)
-0.29 -16 -30 -20 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.21 -16 -29 -18 -19
Valuation Ratios
- - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 427.99 70.45 119.42 63.80
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.24 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 570.03 58.38 178.24 49.91
Enterprise Value to EBITDA (EV/EBITDA)
4,140.10 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.35 0.00 0.00 0.00
Leverage & Solvency
- - - - -
Debt to Equity
0.00 -0.94 -0.23 -0.99 0.00
Long-Term Debt to Equity
0.00 -0.92 -0.23 -0.99 0.00
Financial Leverage
0.00 0.09 -0.78 -0.49 -0.33
Leverage Ratio
1.10 1.22 -0.29 -0.96 -0.66
Compound Leverage Factor
0.96 1.22 -0.29 -1.00 -0.70
Debt to Total Capital
0.00% -1,440.21% -29.45% -14,853.97% 0.00%
Short-Term Debt to Total Capital
0.00% -19.06% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% -1,421.15% -29.45% -14,853.97% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
109.46% 0.00% 0.00% 0.00% -3.32%
Common Equity to Total Capital
-9.46% 1,540.21% 129.45% 14,953.97% 103.32%
Debt to EBITDA
0.00 -2.14 -0.01 -1.04 0.00
Net Debt to EBITDA
0.00 -2.12 0.13 -0.74 0.00
Long-Term Debt to EBITDA
0.00 -2.11 -0.01 -1.04 0.00
Debt to NOPAT
0.00 -5.55 -0.03 -1.39 0.00
Net Debt to NOPAT
0.00 -5.52 0.30 -0.98 0.00
Long-Term Debt to NOPAT
0.00 -5.48 -0.03 -1.39 0.00
Altman Z-Score
6.81 -143.08 -54.09 -39.57 -60.07
Noncontrolling Interest Sharing Ratio
109.45% 120.71% 0.00% 0.00% -1.28%
Liquidity Ratios
- - - - -
Current Ratio
0.32 0.65 1.02 1.18 0.54
Quick Ratio
0.06 0.09 0.61 0.84 0.33
Cash Flow Metrics
- - - - -
Free Cash Flow to Firm (FCFF)
0.00 385 -9.91 -14 -4.99
Operating Cash Flow to CapEx
0.00% -4,038.99% -11,170.59% -1,831.53% -10,168.16%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 -17.36 -3.14
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 -22.00 -11.45
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 -23.20 -11.56
Efficiency Ratios
- - - - -
Asset Turnover
0.00 0.00 0.06 0.02 0.02
Accounts Receivable Turnover
0.00 0.00 2.20 0.42 0.55
Inventory Turnover
0.00 0.00 0.58 0.48 0.54
Fixed Asset Turnover
0.00 0.00 0.93 0.28 0.21
Accounts Payable Turnover
0.00 0.61 0.62 0.46 0.38
Days Sales Outstanding (DSO)
0.00 0.00 165.75 863.02 659.57
Days Inventory Outstanding (DIO)
0.00 0.00 624.29 765.42 679.47
Days Payable Outstanding (DPO)
0.00 594.31 591.45 788.54 954.68
Cash Conversion Cycle (CCC)
0.00 -594.31 198.60 839.90 384.36
Capital & Investment Metrics
- - - - -
Invested Capital
388 -2.65 -5.59 -4.91 -16
Invested Capital Turnover
0.00 0.00 -0.08 -0.04 -0.02
Increase / (Decrease) in Invested Capital
0.00 -391 -2.94 0.68 -11
Enterprise Value (EV)
871 135 18 40 12
Market Capitalization
446 101 22 27 15
Book Value per Share
($0.69) ($0.68) ($0.09) ($1.00) ($0.52)
Tangible Book Value per Share
($0.69) ($0.68) ($0.09) ($1.00) ($0.52)
Total Capital
388 -2.35 -1.37 -0.13 -12
Total Debt
0.00 34 0.40 19 0.00
Total Long-Term Debt
0.00 33 0.40 19 0.00
Net Debt
-0.15 34 -3.81 13 -3.74
Capital Expenditures (CapEx)
0.00 0.22 0.15 0.98 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.96 -0.61 -4.05 -4.13 -9.02
Debt-free Net Working Capital (DFNWC)
-1.82 -0.42 0.17 1.36 -5.28
Net Working Capital (NWC)
-1.82 -0.87 0.17 1.36 -5.28
Net Nonoperating Expense (NNE)
-3.39 9.83 17 7.32 8.17
Net Nonoperating Obligations (NNO)
-0.15 34 -3.81 14 -3.74
Total Depreciation and Amortization (D&A)
0.50 0.08 0.74 2.04 2.86
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -255.70% -1,280.70% -1,833.33% -3,743.57%
Debt-free Net Working Capital to Revenue
0.00% -178.48% 54.11% 603.56% -2,192.12%
Net Working Capital to Revenue
0.00% -367.51% 54.11% 603.56% -2,192.12%
Earnings Adjustments
- - - - -
Adjusted Basic Earnings per Share
$0.00 $0.72 ($2.38) ($1.49) ($1.23)
Adjusted Weighted Average Basic Shares Outstanding
0.00 53.13M 12.55M 18.79M 23.26M
Adjusted Diluted Earnings per Share
$0.00 $0.72 ($2.38) ($1.49) ($1.23)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 53.13M 12.55M 18.79M 23.26M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 19.60M 21.33M 76.88M
Normalized Net Operating Profit after Tax (NOPAT)
-3.64 -6.09 -13 -13 -16
Normalized NOPAT Margin
0.00% -2,571.39% -4,066.87% -5,990.76% -6,468.46%
Pre Tax Income Margin
0.00% -6,718.57% -9,468.99% -9,242.22% -9,857.26%
Debt Service Ratios
- - - - -
EBIT to Interest Expense
0.00 0.00 0.00 -24.48 -13.94
NOPAT to Interest Expense
0.00 0.00 0.00 -16.52 -9.80
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 -25.69 -14.05
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 -17.72 -9.92
Payout Ratios
- - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% -11.77% -7.66%
Augmented Payout Ratio
-3,630.02% 0.00% 0.00% -11.77% -7.92%

Quarterly Metrics And Ratios for Envoy Medical

This table displays calculated financial ratios and metrics derived from Envoy Medical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 76,881,110.00 77,194,595.00
DEI Adjusted Shares Outstanding
39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 39,099,964.00 76,881,110.00 7,719,459.00
DEI Earnings Per Adjusted Shares Outstanding
-0.20 -0.14 -0.19 -0.20 -0.16 -0.18 -0.20 -0.20 -0.15 -0.09 -0.68
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-24.36% 7.94% -30.00% -55.79% -22.03% 14.71% -25.00% 78.57% -15.22% -34.62% 57.14%
EBITDA Growth
55.16% 74.76% -421.17% 17.80% 37.61% -23.26% -2.13% -76.09% -9.49% -37.94% 30.51%
EBIT Growth
52.96% 71.20% -464.43% 15.08% 27.77% -32.79% -5.53% -55.55% 3.38% -18.08% 34.59%
NOPAT Growth
-29.51% -8.30% -2.82% 32.35% -4.57% -4.49% -14.80% -40.39% -16.68% -9.84% -5.17%
Net Income Growth
52.69% 70.20% -481.32% 7.38% 20.29% -44.16% -8.76% -42.62% 12.95% -5.13% 39.34%
EPS Growth
68.70% 0.00% -400.00% 0.00% 29.27% -10.34% 10.26% 32.50% 72.41% 78.13% 39.34%
Operating Cash Flow Growth
-85.62% -15.17% -338.67% 54.32% 33.35% 4.00% -65.12% -11.67% -62.71% -22.33% -16.14%
Free Cash Flow Firm Growth
-91.21% -93.10% -100.71% -119.49% -126.01% -114.59% 48.74% 258.51% 148.01% 274.31% 162.49%
Invested Capital Growth
-145.85% -124.16% -6.74% 12.24% 43.55% 4.25% -28.96% -216.06% -128.60% -191.86% -41.70%
Revenue Q/Q Growth
-37.89% 15.25% -17.65% -25.00% 9.52% 69.57% -46.15% 78.57% -48.00% 30.77% 29.41%
EBITDA Q/Q Growth
-36.76% 43.74% -53.27% 30.30% -3.82% -11.14% -26.99% -20.18% 35.45% -40.01% 36.02%
EBIT Q/Q Growth
-25.03% 38.80% -49.31% 25.67% -6.35% -12.50% -18.65% -9.57% 33.94% -37.49% 34.27%
NOPAT Q/Q Growth
27.35% 0.66% -2.47% 8.53% -12.29% 0.72% -12.58% -11.86% 6.67% 6.54% 0.57%
Net Income Q/Q Growth
-25.75% 37.05% -51.00% 22.52% -8.23% -13.85% -13.92% -1.60% 33.94% -37.49% 34.27%
EPS Q/Q Growth
0.00% 29.27% -34.48% -2.56% 27.50% -10.34% -9.38% 22.86% 70.37% 12.50% 34.27%
Operating Cash Flow Q/Q Growth
49.85% 16.87% 43.54% -94.09% 26.83% -19.73% 2.89% -31.26% -6.61% 9.98% 7.81%
Free Cash Flow Firm Q/Q Growth
1,962.01% -20.77% -111.30% -31.67% -120.68% 55.57% 60.30% 507.18% -33.16% 61.30% -88.70%
Invested Capital Q/Q Growth
-103.76% 49.78% -50.30% 42.93% -31.06% 14.82% -102.43% -39.86% 5.20% -8.75% 1.72%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-159.32% -260.29% -233.93% -273.81% -391.30% -200.00% -383.33% -181.33% -702.56% -445.10% -269.70%
EBITDA Margin
-10,050.85% -4,905.88% -9,130.36% -8,485.71% -8,043.48% -5,271.79% -12,433.33% -8,368.00% -10,387.18% -11,121.57% -5,498.48%
Operating Margin
-8,277.97% -7,135.29% -8,878.57% -10,828.57% -11,102.17% -6,500.00% -13,590.48% -8,513.33% -15,279.49% -10,919.61% -8,389.39%
EBIT Margin
-10,566.10% -5,610.29% -10,171.43% -10,080.95% -9,789.13% -6,494.87% -14,311.90% -8,781.33% -11,156.41% -11,729.41% -5,957.58%
Profit (Net Income) Margin
-10,627.12% -5,804.41% -10,642.86% -10,995.24% -10,865.22% -7,294.87% -15,433.33% -8,781.33% -11,156.41% -11,729.41% -5,957.58%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.58% 103.46% 104.63% 109.07% 110.99% 112.32% 107.84% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-255.92% -168.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-116.19% -184.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
27.05% -105.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-228.87% -273.86% 307.98% 201.72% 123.42% 100.68% 167.21% 155.22% 338.05% 178.87% 480.94%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-115.37% -65.44% -184.74% -229.01% -220.02% -173.33% -338.70% -210.62% -129.86% -143.46% -100.68%
Return on Assets (ROA)
-116.04% -67.71% -193.30% -249.78% -244.20% -194.68% -365.24% -210.62% -129.86% -143.46% -100.68%
Return on Common Equity (ROCE)
347.75% 795.75% 307.98% 201.72% 123.42% 100.68% 168.05% 157.21% 347.72% 181.55% 509.83%
Return on Equity Simple (ROE_SIMPLE)
309.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.42 -3.40 -3.48 -3.18 -3.57 -3.55 -4.00 -4.47 -4.17 -3.90 -3.88
NOPAT Margin
-5,794.58% -4,994.71% -6,215.00% -7,580.00% -7,771.52% -4,550.00% -9,513.33% -5,959.33% -10,695.64% -7,643.73% -5,872.58%
Net Nonoperating Expense Percent (NNEP)
-139.73% 16.85% -170.54% 28.34% 20.60% 13.79% 77.99% 41.51% -4.82% 88.61% -0.62%
Return On Investment Capital (ROIC_SIMPLE)
53.90% 85.47% 83.40% 2,526.67% 319.76% 289.95% 52.16% 36.76% -41.05% -118.02% 253.16%
Cost of Revenue to Revenue
259.32% 360.29% 333.93% 373.81% 491.30% 300.00% 483.33% 281.33% 802.56% 545.10% 369.70%
SG&A Expenses to Revenue
3,567.80% 2,333.82% 3,017.86% 3,438.10% 3,958.70% 2,651.28% 5,814.29% 2,133.33% 4,817.95% 3,978.43% 3,219.70%
R&D to Revenue
4,000.00% 3,810.29% 4,923.21% 5,883.33% 5,973.91% 3,185.90% 6,428.57% 6,070.67% 9,338.46% 6,141.18% 4,662.12%
Operating Expenses to Revenue
8,118.64% 6,875.00% 8,644.64% 10,554.76% 10,710.87% 6,300.00% 13,207.14% 8,332.00% 14,576.92% 10,474.51% 8,119.70%
Earnings before Interest and Taxes (EBIT)
-6.23 -3.82 -5.70 -4.23 -4.50 -5.07 -6.01 -6.59 -4.35 -5.98 -3.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-5.93 -3.34 -5.11 -3.56 -3.70 -4.11 -5.22 -6.28 -4.05 -5.67 -3.63
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.51 24.95 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.51 24.95 0.00
Price to Revenue (P/Rev)
245.49 145.35 217.64 119.42 130.78 136.78 81.49 63.80 195.93 398.06 307.66
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
232.45 167.43 253.36 178.24 214.71 241.95 65.02 49.91 89.70 304.88 246.28
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
3.05 3.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-0.14 -0.68 -0.77 -0.99 -0.95 -0.96 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-0.14 -0.68 -0.77 -0.99 -0.95 -0.96 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.23 0.57 0.21 -0.49 -0.44 -0.74 -0.24 -0.33 0.55 -0.18 2.09
Leverage Ratio
3.10 4.53 -2.23 -0.96 -0.60 -0.39 -0.67 -0.66 -2.94 -1.29 -3.15
Compound Leverage Factor
3.12 4.69 -2.33 -1.05 -0.66 -0.44 -0.73 -0.66 -2.94 -1.29 -3.15
Debt to Total Capital
-16.87% -211.70% -344.02% -14,853.97% -2,066.73% -2,339.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-16.87% -211.70% -344.02% -14,853.97% -2,066.73% -2,339.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.73% -3.32% 3.71% 10.58% -34.30%
Common Equity to Total Capital
116.87% 311.70% 444.02% 14,953.97% 2,166.73% 2,439.46% 101.73% 103.32% 96.29% 89.42% 134.30%
Debt to EBITDA
-0.05 -0.63 -0.77 -1.04 -1.47 -1.74 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.17 -0.50 -0.53 -0.74 -1.13 -1.42 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.05 -0.63 -0.77 -1.04 -1.47 -1.74 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.08 -0.61 -0.96 -1.39 -1.69 -2.08 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.28 -0.48 -0.66 -0.98 -1.31 -1.69 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.08 -0.61 -0.96 -1.39 -1.69 -2.08 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-43.26 -57.14 -42.27 -35.07 -40.07 -43.40 -54.53 -54.07 -13.40 -16.99 -22.61
Noncontrolling Interest Sharing Ratio
251.94% 390.57% 0.00% 0.00% 0.00% 0.00% -0.50% -1.28% -2.86% -1.49% -6.01%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.10 0.62 0.79 1.18 1.09 0.94 0.64 0.54 2.27 1.73 1.21
Quick Ratio
0.74 0.24 0.51 0.84 0.71 0.67 0.40 0.33 2.07 1.56 1.03
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
33 26 -2.94 -3.87 -8.53 -3.79 -1.51 6.13 4.10 6.61 0.75
Operating Cash Flow to CapEx
-5,127.52% -588.10% -426.50% 0.00% -62,083.33% -446,000.00% 0.00% -3,305.23% 0.00% -90,933.33% -18,629.63%
Free Cash Flow to Firm to Interest Expense
911.40 196.94 -11.13 -10.07 -17.24 -6.08 -3.20 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-155.25 -35.20 -9.94 -13.26 -7.53 -7.15 -9.20 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-158.28 -41.18 -12.27 -11.87 -7.54 -7.15 -9.20 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.01 0.02
Accounts Receivable Turnover
0.00 0.00 0.42 0.42 1.48 1.68 1.47 0.55 4.14 3.21 3.79
Inventory Turnover
0.00 0.00 0.56 0.48 0.52 0.51 0.50 0.54 0.61 0.63 0.66
Fixed Asset Turnover
0.00 0.00 0.35 0.28 0.28 0.25 0.18 0.21 0.21 0.20 0.23
Accounts Payable Turnover
0.62 0.56 0.33 0.46 0.63 0.50 0.37 0.38 0.57 0.55 0.49
Days Sales Outstanding (DSO)
0.00 0.00 878.36 863.02 246.20 217.85 248.31 659.57 88.13 113.73 96.39
Days Inventory Outstanding (DIO)
0.00 0.00 653.81 765.42 696.86 719.33 730.00 679.47 597.64 574.92 549.42
Days Payable Outstanding (DPO)
589.81 648.53 1,105.76 788.54 576.61 728.18 987.73 954.68 638.47 663.54 743.96
Cash Conversion Cycle (CCC)
-589.81 -648.53 426.42 839.90 366.45 209.00 -9.42 384.36 47.30 25.12 -98.15
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-11 -5.72 -8.60 -4.91 -6.43 -5.48 -11 -16 -15 -16 -16
Invested Capital Turnover
0.04 0.03 -0.03 -0.04 -0.02 -0.04 -0.02 -0.02 -0.02 -0.02 -0.02
Increase / (Decrease) in Invested Capital
-36 -29 -0.54 0.68 4.96 0.24 -2.49 -11 -8.27 -11 -4.62
Enterprise Value (EV)
69 51 70 40 46 54 14 12 21 63 57
Market Capitalization
73 44 61 27 28 30 17 15 46 82 71
Book Value per Share
($0.38) ($0.67) ($1.00) ($1.00) ($1.14) ($1.40) ($0.35) ($0.52) $0.15 $0.04 ($0.02)
Tangible Book Value per Share
($0.38) ($0.67) ($1.00) ($1.00) ($1.14) ($1.40) ($0.35) ($0.52) $0.15 $0.04 ($0.02)
Total Capital
-6.34 -3.97 -4.17 -0.13 -1.12 -1.22 -7.53 -12 11 3.69 -1.14
Total Debt
1.07 8.41 14 19 23 29 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
1.07 8.41 14 19 23 29 0.00 0.00 0.00 0.00 0.00
Net Debt
-3.88 6.67 9.93 13 18 23 -3.56 -3.74 -25 -20 -15
Capital Expenditures (CapEx)
0.11 0.79 0.62 -0.53 0.01 0.00 0.00 0.17 0.00 0.01 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.21 -4.81 -6.36 -4.13 -4.60 -5.77 -6.79 -9.02 -9.78 -10 -12
Debt-free Net Working Capital (DFNWC)
0.73 -3.06 -1.94 1.36 0.72 -0.49 -3.23 -5.28 15 9.28 2.99
Net Working Capital (NWC)
0.73 -3.06 -1.94 1.36 0.72 -0.49 -3.23 -5.28 15 9.28 2.99
Net Nonoperating Expense (NNE)
2.85 0.55 2.48 1.43 1.42 2.14 2.49 2.12 0.18 2.08 0.06
Net Nonoperating Obligations (NNO)
-3.98 6.67 9.93 14 18 24 -3.56 -3.74 -25 -20 -15
Total Depreciation and Amortization (D&A)
0.30 0.48 0.58 0.67 0.80 0.95 0.79 0.31 0.30 0.31 0.30
Debt-free, Cash-free Net Working Capital to Revenue
-1,417.85% -1,592.05% -2,288.49% -1,833.33% -2,167.45% -2,600.90% -3,262.98% -3,743.57% -4,179.49% -5,022.22% -5,012.12%
Debt-free Net Working Capital to Revenue
247.14% -1,013.91% -697.12% 603.56% 338.21% -219.37% -1,553.37% -2,192.12% 6,611.54% 4,484.54% 1,295.24%
Net Working Capital to Revenue
247.14% -1,013.91% -697.12% 603.56% 338.21% -219.37% -1,553.37% -2,192.12% 6,611.54% 4,484.54% 1,295.24%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.27) ($0.37) ($0.40) ($0.29) ($0.32) ($0.35) ($0.27) ($0.08) ($0.07) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding
19.60M 19.60M 19.62M 18.79M 21.33M 21.38M 21.85M 23.26M 68.93M 104.04M 10.43M
Adjusted Diluted Earnings per Share
($0.32) $0.00 ($0.37) ($0.40) ($0.29) ($0.32) ($0.35) ($0.27) ($0.08) ($0.07) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding
19.60M 19.60M 19.62M 18.79M 21.33M 21.38M 21.85M 23.26M 68.93M 104.04M 10.43M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
19.60M 19.60M 20.24M 21.33M 21.33M 21.52M 28.79M 76.88M 76.88M 77.19M 7.74M
Normalized Net Operating Profit after Tax (NOPAT)
-3.42 -3.40 -3.48 -3.18 -3.57 -3.55 -4.00 -4.47 -4.17 -3.90 -3.88
Normalized NOPAT Margin
-5,794.58% -4,994.71% -6,215.00% -7,580.00% -7,771.52% -4,550.00% -9,513.33% -5,959.33% -10,695.64% -7,643.73% -5,872.58%
Pre Tax Income Margin
-10,627.12% -5,804.41% -10,642.86% -10,995.24% -10,865.22% -7,294.87% -15,433.33% -8,781.33% -11,156.41% -11,729.41% -5,957.58%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-173.17 -28.90 -21.58 -11.03 -9.10 -8.12 -12.76 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-94.97 -25.73 -13.18 -8.29 -7.22 -5.69 -8.48 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-176.19 -34.89 -23.91 -9.64 -9.11 -8.12 -12.76 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-97.99 -31.72 -15.51 -6.90 -7.23 -5.69 -8.48 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% -8.66% -11.77% -18.75% -20.06% -11.17% -7.66% -2.62% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -8.66% -11.77% -18.75% -20.06% -11.17% -7.92% -2.62% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Envoy Medical’s latest quarter shows a company still in the development stage, with minimal revenue and substantial operating costs. Q2 2026 revenue increased to $51,000 from $39,000 in Q1, but remained below $78,000 in Q2 2025 and $68,000 in Q2 2024. Cost of revenue was $278,000, producing a gross loss of $227,000. Research and development remained the largest expense at $3.1 million, while total operating expenses were $5.3 million.

Profitability remains a significant challenge. Envoy reported a $6.0 million net loss in Q2 2026, compared with a $4.4 million loss in Q1 and a $5.7 million loss in Q2 2025. The company’s loss attributable to common shareholders was $7.3 million after $1.3 million of preferred stock dividends. Operating cash flow was negative $5.5 million, and cash declined from $25.3 million at the end of Q1 to $19.7 million at June 30, 2026.

The balance sheet has improved from 2025, primarily because of capital raising. Total liabilities declined to $20.3 million from $39.8 million at June 30, 2025, and shareholders’ equity turned positive at $3.3 million. However, the company continues to consume cash and has relied heavily on equity and debt financing. The Q1 2026 equity issuance of $27.8 million also contributed to a sharp increase in weighted-average basic shares, from 21.4 million in Q2 2025 to 104.0 million in Q2 2026.

  • Cash balance remains meaningful: Envoy held $19.7 million in cash and equivalents at the end of Q2 2026, providing near-term funding for research and development.
  • Balance sheet improved year over year: Total liabilities fell from $39.8 million in Q2 2025 to $20.3 million in Q2 2026, while total equity improved from negative $29.9 million to positive $3.3 million.
  • Operating expenses declined sequentially: Total operating expenses fell from $5.7 million in Q1 2026 to $5.3 million in Q2, led by lower research and development spending.
  • Revenue remains highly volatile and immaterial: Q2 revenue rose sequentially to $51,000, but the company has not established a consistent growth trend and continues to report negative gross profit.
  • Persistent operating losses: Envoy has reported large net losses throughout the supplied 2024-2026 periods, with the Q2 2026 loss reaching $6.0 million.
  • Cash burn remains high: Operating cash flow was negative $5.5 million in Q2 2026, while total cash declined by $5.6 million during the quarter.
  • Limited revenue does not cover expenses: Q2 revenue of $51,000 was only a small fraction of the $5.3 million in operating expenses, leaving the company dependent on outside financing.
  • Significant dilution risk: Weighted-average basic shares increased to 104.0 million in Q2 2026 from 68.9 million in Q1 and 21.4 million in Q2 2025, reducing the ownership percentage of existing shareholders.
  • Preferred stock dividends increase the common-stock loss: The $1.3 million preferred dividend in Q2 2026 increased the loss attributable to common shareholders to $7.3 million.
  • Future financing remains likely: At the Q2 operating cash-burn rate, the company’s cash balance represents only several quarters of funding, although the actual runway will depend on spending, financing activity and commercialization progress.
11/20/26 07:17 AM ETAI Generated. May Contain Errors.

Envoy Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Envoy Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Envoy Medical's net income appears to be on a downward trend, with a most recent value of -$23.76 million in 2025, falling from -$251.63 thousand in 2021. The previous period was -$20.80 million in 2024. Check out Envoy Medical's forecast to explore projected trends and price targets.

Envoy Medical's total operating income in 2025 was -$22.27 million, based on the following breakdown:
  • Total Gross Profit: -$633 thousand
  • Total Operating Expenses: $21.64 million

Over the last 4 years, Envoy Medical's total revenue changed from $0.00 in 2021 to $241 thousand in 2025, a change of 24,100,000.0%.

In the past 12 quarters, Envoy Medical's cash and equivalents has ranged from $1.75 million in Q2 2024 to $25.25 million in Q1 2026, and is currently $14.57 million as of their latest financial filing in Q3 2026.

Envoy Medical had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2021.

Over the last 4 years, Envoy Medical's book value per share changed from -0.69 in 2021 to -0.52 in 2025, a change of 24.4%.



Financial statements for NASDAQ:COCH last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners